[go: up one dir, main page]

JOP20190257A1 - مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats - Google Patents

مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats

Info

Publication number
JOP20190257A1
JOP20190257A1 JOP/2019/0257A JOP20190257A JOP20190257A1 JO P20190257 A1 JOP20190257 A1 JO P20190257A1 JO P20190257 A JOP20190257 A JO P20190257A JO P20190257 A1 JOP20190257 A1 JO P20190257A1
Authority
JO
Jordan
Prior art keywords
bicyclic heteroaryl
fused bicyclic
heteroaryl compounds
present
lats
Prior art date
Application number
JOP/2019/0257A
Other languages
English (en)
Inventor
Dirk Behnke
Jun Liu
Juergen Klaus Maibaum
Tingting Mo
Arnaud Lacoste
Timothy Hoffman
Yefen Zou
Yahu Liu
Xueshi Hao
Frada Berenshteyn
Jan Tchorz
Yun Feng Xie
Shanshan Yan
Jianfeng Pan
Cameron Lee
Qihui Jin
Xin Qu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20190257A1 publication Critical patent/JOP20190257A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/085—Coculture with; Conditioned medium produced by cells of the nervous system eye cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/27—Lung cells, respiratory tract cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 بالصيغة A2 أو A1 واستخدامها كمثبطات LATS، أو ملح، أيزومر فراغي أو تركيبة صيدلانية منها؛ حيث تكون المتغيرات كما تم تعريفها في هذه الوثيقة. يتعلق الاختراع الحالي أيضاً بطريقة لتثبيط LATS في مجموعة خلايا باستخدام مركب بالصيغة A1، أو ملح، أيزومر فراغي أو تركيبة صيدلانية منها. يقدم الاختراع الحالي أيضاً طريقة لتصنيع مركبات الاختراع، واستخداماتها العلاجية. يقدم الاختراع أيضاً طرق لتحضيرها، واستخدامها الطبي، واستخدامها في معالجة وإدارة الأمراض أو الاضطرابات. الشكل 1 و صور A1, A2
JOP/2019/0257A 2017-04-28 2017-06-16 مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats JOP20190257A1 (ar)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762491484P 2017-04-28 2017-04-28
US201762491573P 2017-04-28 2017-04-28
US201762491475P 2017-04-28 2017-04-28
US201762491526P 2017-04-28 2017-04-28
US201862650232P 2018-03-29 2018-03-29

Publications (1)

Publication Number Publication Date
JOP20190257A1 true JOP20190257A1 (ar) 2019-10-28

Family

ID=62148436

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0257A JOP20190257A1 (ar) 2017-04-28 2017-06-16 مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats

Country Status (25)

Country Link
US (2) US11458138B2 (ar)
EP (1) EP3615537B1 (ar)
JP (2) JP7247102B2 (ar)
KR (1) KR20190142776A (ar)
CN (3) CN114703144A (ar)
AU (2) AU2018260495B2 (ar)
BR (1) BR112019022512A2 (ar)
CA (1) CA3056906A1 (ar)
CL (1) CL2019003049A1 (ar)
CO (1) CO2019011873A2 (ar)
CR (1) CR20190483A (ar)
CU (2) CU20200080A7 (ar)
DO (1) DOP2019000273A (ar)
EC (1) ECSP19076732A (ar)
ES (1) ES2983611T3 (ar)
IL (2) IL269293B (ar)
JO (1) JOP20190257A1 (ar)
MA (1) MA49285A (ar)
MX (1) MX2019012756A (ar)
PE (1) PE20200292A1 (ar)
PH (1) PH12019502436A1 (ar)
SG (1) SG11201908615RA (ar)
TW (1) TW201843140A (ar)
UY (1) UY37703A (ar)
WO (1) WO2018198077A2 (ar)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126373C2 (uk) 2015-12-04 2022-09-28 Новартіс Аг Композиція і спосіб для імуноонкології
CA3054621A1 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
LT3687996T (lt) 2017-09-27 2022-01-10 Incyte Corporation Pirolotriazino darinių druskos, naudingos kaip tam inhibitoriai
WO2019235569A1 (ja) 2018-06-08 2019-12-12 日産化学株式会社 キナーゼ阻害剤
SG11202013163TA (en) 2018-06-29 2021-01-28 Incyte Corp Formulations of an axl/mer inhibitor
WO2020081673A1 (en) * 2018-10-16 2020-04-23 The Schepens Eye Research Institute, Inc. Bioadhesive for soft tissue repair
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
US20220017888A1 (en) * 2018-12-11 2022-01-20 Kyoto University Method for inducing deletion in genomic dna
EP3915636A4 (en) 2019-01-30 2022-03-09 Nissan Chemical Corporation HYDRAZIDE COMPOUND AND KINASE INHIBITOR
CN112707905B (zh) * 2019-10-25 2024-07-02 武汉誉祥医药科技有限公司 一种三并杂环化合物及其制备方法和用途
GB201915829D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
CN114786778A (zh) * 2019-11-27 2022-07-22 基因泰克公司 治疗性化合物
JP7678595B2 (ja) 2020-02-05 2025-05-16 ザ ロックフェラー ユニバーシティー ピロロ［２，３‐ｂ］ピリジン‐３‐カルボキサミド組成物及び聴力損失を改善するための方法
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN111443068B (zh) * 2020-03-06 2023-06-27 天津大学 具有多重刺激响应特性的纯有机室温磷光材料及筛选方法和应用
JP2023522784A (ja) 2020-04-27 2023-05-31 ノバルティス アーゲー 眼細胞療法のための方法及び組成物
MX2022013518A (es) * 2020-04-28 2023-02-01 Global Blood Therapeutics Inc Pirimidinas cicloalquiladas como inhibidores de la ferroportina.
CN112305126A (zh) * 2020-11-02 2021-02-02 宁夏贝利特生物科技有限公司 一种硝酸胍含量的测定方法
CN117795330A (zh) * 2021-08-23 2024-03-29 Emd密理博公司 用于光聚合电泳凝胶的系统和方法
CN115974868B (zh) * 2022-11-07 2024-04-12 安徽理工大学 一种尿嘧啶衍生物的合成方法及其抗肺纤维化方面的潜在应用
WO2024211621A1 (en) * 2023-04-04 2024-10-10 Children's Hospital Los Angeles Lats kinase inhibitor to treat retinal degeneration

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065392A1 (en) 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
KR20070113252A (ko) 2005-02-25 2007-11-28 쿠도스 파마슈티칼스 리미티드 2,4-디아미노-피리도피리미딘 유도체 및 이의 ｍＴＯＲ억제제로서의 용도
CA2682339A1 (en) 2007-04-06 2008-10-16 Novartis Ag 2 , 6-naphthyridine derivatives as protein kinase modulators
ES2432821T3 (es) 2008-07-31 2013-12-05 Genentech, Inc. Compuestos de pirimidina, composiciones y métodos de utilización
US20110319409A1 (en) * 2010-06-23 2011-12-29 Cox Christopher D 7-aza-quinazoline pde10 inhibitors
US9347041B2 (en) 2011-07-15 2016-05-24 Osaka University Method for preparing corneal endothelial cell
AR088061A1 (es) 2011-09-27 2014-05-07 Hoffmann La Roche Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
WO2014052699A1 (en) 2012-09-28 2014-04-03 Cephalon, Inc. Azaquinazoline inhibitors of atypical protein kinase c
ES2765481T3 (es) * 2013-12-12 2020-06-09 Broad Inst Inc Administración, uso y aplicaciones terapéuticas de los sistemas crispr-cas y composiciones para la edición genómica
TWI675836B (zh) * 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑
EP3197557A1 (en) 2014-09-24 2017-08-02 Friedrich Miescher Institute for Biomedical Research Lats and breast cancer
TW201718536A (zh) 2015-08-03 2017-06-01 必治妥美雅史谷比公司 可作為ＴＮＦα調節劑之雜環化合物
WO2017035116A1 (en) 2015-08-25 2017-03-02 President And Fellows Of Harvard College Methods and compositions relating to the diagnosis and treatment of cancer
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
UY38427A (es) * 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares

Also Published As

Publication number Publication date
SG11201908615RA (en) 2019-11-28
MX2019012756A (es) 2019-12-16
AU2018260495A1 (en) 2019-10-17
JP2022188056A (ja) 2022-12-20
PH12019502436A1 (en) 2020-07-20
ES2983611T3 (es) 2024-10-23
CU20190086A7 (es) 2020-11-30
IL269293A (en) 2019-11-28
AU2021286281A1 (en) 2022-01-06
US11458138B2 (en) 2022-10-04
EP3615537A2 (en) 2020-03-04
CU20200080A7 (es) 2021-05-12
EP3615537B1 (en) 2024-03-06
UY37703A (es) 2018-11-30
IL292857A (en) 2022-07-01
TW201843140A (zh) 2018-12-16
CR20190483A (es) 2019-11-20
DOP2019000273A (es) 2019-12-15
KR20190142776A (ko) 2019-12-27
WO2018198077A2 (en) 2018-11-01
RU2019138304A (ru) 2021-05-28
CN110573511A (zh) 2019-12-13
CN114703144A (zh) 2022-07-05
IL269293B (en) 2022-06-01
MA49285A (fr) 2020-03-04
JP7247102B2 (ja) 2023-03-28
BR112019022512A2 (pt) 2020-06-16
CN114621222B (zh) 2024-12-17
CN114621222A (zh) 2022-06-14
US20180344738A1 (en) 2018-12-06
AU2018260495B2 (en) 2021-09-16
PE20200292A1 (es) 2020-02-05
US20230190751A1 (en) 2023-06-22
CO2019011873A2 (es) 2020-01-17
CL2019003049A1 (es) 2020-02-07
RU2019138304A3 (ar) 2021-07-13
CA3056906A1 (en) 2018-11-01
CN110573511B (zh) 2023-04-25
ECSP19076732A (es) 2019-10-31
JP2020517698A (ja) 2020-06-18
WO2018198077A3 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
JOP20190257A1 (ar) مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
TW201612158A (en) Amide derivatives and salts thereof, preparation process and pharmaceutical use thereof
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
WO2014100071A3 (en) Substituted pyrrolopyrimidines as hdm2 inhibitors
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
NZ726366A (en) Syk inhibitors
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
MX2017015456A (es) Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MY163235A (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
PH12021553248A1 (en) Heterocyclic monoacylglycerol lipase (magl) inhibitors
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
MX394882B (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta)
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators